Status:
RECRUITING
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
Lead Sponsor:
Deling Li
Collaborating Sponsors:
Peking Union Medical College Hospital
Conditions:
Craniopharyngioma
Eligibility:
All Genders
14-80 years
Phase:
NA
Brief Summary
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
Detailed Description
The trophoblast cell surface antigen 2 (Trop2), encoded by the TACSTD2 gene, is a transmembrane glycoprotein that regulates epithelial malignant transformation and proliferation. Trop2 has been report...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- must be able to provide a written informed consent
- radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
- adequate clinical condition (Karnofsky performance status ≥70)
- Exclusion criteria:
- concomitant major central nervous system disorders
- severe hepatic or renal dysfunction
- history of severe allergy or hypersensitivity to intravenous radiographic contrast agents
- claustrophobia precluding PET/CT or MRI examinations
- pregnancy or breastfeeding
Exclusion
Key Trial Info
Start Date :
July 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07177482
Start Date
July 4 2025
End Date
December 31 2026
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070